IMR Press / FBL / Volume 12 / Issue 9 / DOI: 10.2741/2314

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Heparin-induced thrombocytopenia: impact of bovine versus porcine heparin in HIT pathogenesis
Show Less
1 Florida Hospital Medical Center, Cancer Institute, Orlando, FL 32804, USA
Academic Editor:Pudur Jagadeeswaran
Front. Biosci. (Landmark Ed) 2007, 12(9), 3312–3320; https://doi.org/10.2741/2314
Published: 1 May 2007
(This article belongs to the Special Issue The zebrafish as a model for human disease)
Abstract

Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy in cardiovascular/hematologic indications. Heparin is a mixture of sulfated mucopolysaccharide with heterogeneity and is capable of forming multiple complexes with platelet factor 4 (PF4), released from activated platelets. HPF4 antibodies may cause platelet/endothelial cell activation to promote HIT pathogenesis. HIT is a clinico-pathologic syndrome and its diagnosis primarily remains a clinical one; however, the serologic confirmation of the presence of HPF4 antibodies is also necessary part of the evaluation. Assays are based on the immunodetection of HPF4 antibodies and/or their functional ability to activate cells. Currently, there are several assays in use and a few newer/rapid immunoassays are becoming available. Recent studies have confirmed that HPF4 antibody generation (seroconversion) is common after cardiac surgery and suggest that patients receiving bovine heparin are more likely to generate functional (pathogenic) HPF4 antibodies of the IgG subclass. Thus, the use of bovine heparin in cardiovascular surgery should be avoided. A brief account of the currently available options for the management of HIT patients with non-heparin anticoagulants is provided.

Share
Back to top